Scottsdale, AZNCT05919264Now EnrollingIRB Ready

Cancer Clinical Trial in Scottsdale, AZ

Access cutting-edge cancer treatment through this phase 1/2 clinical trial at a research site in Scottsdale. Study-provided care at no cost to qualified participants.

Sponsored by Parabilis Medicines, Inc.

Quick Self-Assessment

See if you qualify for this Scottsdale location

Preparing your pre-screening questions…

Expert Care in Scottsdale

Access cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cancer treatment provided free

Apply for This Scottsdale Location

Check if you qualify for this cancer clinical trial in Scottsdale, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Scottsdale

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Scottsdale site if eligible
  4. 4Begin participation

About This Cancer Study in Scottsdale

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.

Sponsor: Parabilis Medicines, Inc.

Who Can Participate

Inclusion Criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ and marrow function. Additional Inclusion Criteria for Dose Escalation Cohorts (Part 1a and Part 1g):
Diagnosis of treatment-refractory advanced/metastatic solid tumor that is non-MSI-H or non-dMMR colorectal cancer (CRC) or any other solid tumor with documented WNT- pathway activating mutations (WPAMs). Additional Inclusion Criteria for Dose Escalation Cohorts (Part 1b):
Diagnosis of treatment-refractory advanced/metastatic non-MSI-H or non-dMMR CRC.
At least one lesion that is suitable for a core needle biopsy. Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1c and Part 2c):
Histologically, cytologically, or radiographically confirmed HCC with a documented WPAM (by local ctDNA or tumor NGS testing) in APC or CTNNB1 Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1d, Part 1h, and Part 2d):
Desmoid tumor (aggressive fibromatosis) Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-1 and Part 2f-1) FOG-001 + FOLFOX + Bevacizumab:
Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR CRC
Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.
One dose of mFOLFOX6 with or without bevacizumab in the unresectable or metastatic setting prior to enrollment is allowed. Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-2 and Part 2f-2): FOG-001 + Nivolumab
Non-MSI-H or non-dMMR (by local testing) CRC with or without liver metastases.
MSI-H CRC or solid tumors that are WPAM and resistant to a-PD-1/PD-L1
Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible Additional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-3 and Part 2f-3): FOG-001 + Trifluridine/Tipiracil + Bevacizumab
Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC
Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible. Monotherapy Dose Optimization (Part 1i): FAP
Diagnosis of phenotypic classical FAP with a documented APC mutation
Post-colectomy \>6 months prior to first dose of study drug administration with measurable duodenal polyp burden Additional Inclusion Criteria for Dose Expansion Cohort (Part 2a):
Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC Additional Inclusion Criteria for Dose Expansion Cohort (Part 2b):
Diagnosis of advanced or metastatic solid tumors with a documented WPAM (by local testing) or equivalent evidence

Exclusion Criteria

Known history of bone metastasis. Bone metastasis are allowed for patients with mCRPC. For participants with FAP, osteomas are allowed.
Evidence of vertebral compression fracture or non-traumatic bone fracture within the past 12 months and who are not receiving antiresorptive therapy.
Osteoporosis, which is defined as a T-score of ≤-2.5 at the lumbar spine (L1 - L4), left (or right) femoral neck or left (or right) total hip as determined by DXA scan.
Uncontrolled inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease)
Unstable/inadequate cardiac function.
Has known meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastases.
Pregnant, lactating, or planning to become pregnant.
Complete colectomy within 6 months of the first dose of study drug administration.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Scottsdale?

Yes, this clinical trial (NCT05919264) has an active research site in Scottsdale, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cancer Treatment Options in Scottsdale, AZ

If you're searching for cancer treatment options in Scottsdale, AZ, this clinical trial (NCT05919264) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Scottsdale research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Scottsdale, AZ

See all breast cancer clinical trials recruiting in Scottsdale — not just this study.

Browse Breast Cancer Trials in Scottsdale →

Browse More Trials by Condition

Breast Cancer TrialsLung Cancer TrialsProstate Cancer TrialsColorectal Cancer TrialsMelanoma TrialsPancreatic Cancer TrialsOvarian Cancer TrialsBladder Cancer TrialsAll Conditions →

Ready to Join in Scottsdale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Scottsdale, AZ